Birinapant monotherapy significantly delayed leukemia progression in 17 of 19 pediatric ALL xenograft models. Two models showed no significant EFS difference from vehicle, underscoring model-dependent activity. [1]
In a Molm13 AML xenograft, median survival was 18 days with vehicle, 22 with birinapant, 26 with 5-azacytidine, and 30 with sequential 5-azacytidine followed by birinapant. The combination benefit cannot be assigned to birinapant alone. [2]
Single-agent activity across pediatric ALL xenografts
Animal study · NOD/SCID or NSG mice carrying 19 pediatric ALL PDXs, including 6 Ph-like PDXs; Methods specify female mice, 6–8 weeks, 20–25 g. [1]
Birinapant delayed leukemia progression in most tested models relative to vehicle, while two models lacked a significant EFS difference. Responses varied substantially by model; these mouse findings do not establish clinical efficacy.
Conditions shared by the study groups
- Vehicle
- Composition not specified in retrieved main text.
- Vehicle control
- Model: NOD/SCID or NSG mice carrying 19 pediatric ALL PDXs, including 6 Ph-like PDXs; Methods specify female mice, 6–8 weeks, 20–25 g.
- Treatment course: Matched control follow-up
- Reported limits: Per-model supplemental data not retrieved; do not infer a uniform analyzed group size.
- Birinapant monotherapy
- Model: NOD/SCID or NSG mice carrying 19 pediatric ALL PDXs, including 6 Ph-like PDXs; Methods specify female mice, 6–8 weeks, 20–25 g.
- Route: Intraperitoneal
- Frequency: Every 3 days
- Treatment course: 5 doses
- Reported limits: Per-model supplemental data not retrieved; do not infer a uniform analyzed group size.
Methods and source locations
Compound reported in the paper: Birinapant; Compound label in the paper: birinapant (SMAC mimetic)
Evidence concerns the reported birinapant material, not an Adooq lot. No salt conversion, purity equivalence or independent stereochemical validation is inferred.
Figure 2A–C and caption; Results, The sensitivity of BCP-ALL to birinapant is replicated in vivo; Methods, In vivo drug treatments and Determination of in vivo treatment response
Leukemia progression delay relative to vehicle: EFS event: peripheral-blood huCD45+ cells reached 25%, or humane endpoint with leukemia-related morbidity; Methods specify two-tailed exact log-rank comparison, P ≤ 0.05. Figure 2C identifies 2 nonsignificant models. — Results, The sensitivity of BCP-ALL to birinapant is replicated in vivo, first paragraph; Figure 2A–C; Methods, Determination of in vivo treatment response and Statistical analysis
Vehicle control · Figure 2A–C; Methods, In vivo drug treatments; Results, The sensitivity of BCP-ALL to birinapant is replicated in vivo
Birinapant monotherapy · Figure 2A–C; Methods, In vivo drug treatments; Results, The sensitivity of BCP-ALL to birinapant is replicated in vivo
Birinapant and sequential 5-azacytidine in an AML xenograft
Animal study · Molm13-GFP/Luc human AML xenografts in 8–12-week-old NSG mice; n=10 initially per group, with 7 or 8 mice per group used for survival after tissue collections. [2]
Median survival was 18 days for vehicle, 22 days for birinapant, 26 days for 5-azacytidine, and 30 days for the sequential combination. The partner drug was active alone; the combination result must not be attributed to birinapant monotherapy.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Vehicle
- Phosphate-buffered saline/50 mM citrate, pH 5.0
- Vehicle control
- Model: Molm13-GFP/Luc human AML xenografts in 8–12-week-old NSG mice; n=10 initially per group, with 7 or 8 mice per group used for survival after tissue collections.
- Treatment course: Control follow-up
- Reported limits: Initially n=10/group; survival reported for 7 or 8/group after tissue collections, exact arm-specific n not stated.
- Birinapant monotherapy
- Model: Molm13-GFP/Luc human AML xenografts in 8–12-week-old NSG mice; n=10 initially per group, with 7 or 8 mice per group used for survival after tissue collections.
- Frequency: Twice weekly
- Treatment course: 4 weeks; begins day 3 after inoculation
- Reported limits: Initially n=10/group; survival reported for 7 or 8/group after tissue collections, exact arm-specific n not stated.
- 5-azacytidine monotherapy
- Model: Molm13-GFP/Luc human AML xenografts in 8–12-week-old NSG mice; n=10 initially per group, with 7 or 8 mice per group used for survival after tissue collections.
- Frequency: Daily
- Treatment course: 5 days; begins day 3 after inoculation
- Reported limits: Initially n=10/group; survival reported for 7 or 8/group after tissue collections, exact arm-specific n not stated.
- Sequential 5-azacytidine then birinapant
- Model: Molm13-GFP/Luc human AML xenografts in 8–12-week-old NSG mice; n=10 initially per group, with 7 or 8 mice per group used for survival after tissue collections.
- Frequency: 5-Aza daily; then birinapant twice weekly
- Treatment course: 5-Aza for 5 days, then birinapant for 4 weeks
- Reported limits: Initially n=10/group; survival reported for 7 or 8/group after tissue collections, exact arm-specific n not stated.
Methods and source locations
Compound reported in the paper: Birinapant; Compound label in the paper: birinapant (SMAC mimetic)
Evidence concerns the reported birinapant material, not an Adooq lot. No salt conversion, purity equivalence or independent stereochemical validation is inferred.
Figure 6D and caption; Methods, Xenograft Studies in NOD/SCID IL2Rγ Null (NSG) Mice; associated Results
Mouse survival: Reported values printed in Figure 6D and Results, not estimated from Kaplan–Meier curves. Methods specify log-rank survival analysis. — Figure 6D; Results, Assessment of Birinapant Alone or Combined With 5-Aza in a Xenograft Mouse Model of Human AML; Methods, Xenograft Studies
Vehicle control · Figure 6D and regimen diagram; Methods, Xenograft Studies; associated Results
Birinapant monotherapy · Figure 6D and regimen diagram; Methods, Xenograft Studies; associated Results
5-azacytidine monotherapy · Figure 6D and regimen diagram; Methods, Xenograft Studies; associated Results
Sequential 5-azacytidine then birinapant · Figure 6D and regimen diagram; Methods, Xenograft Studies; associated Results